Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Open access
Nozue, Tsuyoshi · 2017 · Journal of Atherosclerosis and Thrombosis

Abstract

Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events. However, despite intensive statin therapy, a sizable proportion of statin-treated patients are unable to achieve the recommended target LDL-C levels, and not all patients can avoid future cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis by enhancing the degradation of hepatic low-density lipoprotein receptor (LDLR). Owing to its importance in lipid metabolism, PCSK9 has emerged as a novel pharmacological target for lowering LDL-C levels. In this review, the potential role of circulating PCSK9 as a new biomarker of lipid metabolism is described. Next, previous studies evaluating the effects of lipid-modifying pharmacological agents, particularly statins, on circulating PCSK9 concentrations are summarized. Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increased PCSK9 protein. There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9. Finally, the available therapeutic strategies to inhibit PCSK9 are present. Monoclonal antibodies against PCSK9, in combination with statins, are one of the most promising and novel approaches to achieve further reduction of LDL-C levels and reduce the risk of cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5551/jat.rv17012

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. PCSK9 protein structure PCSK9 comprises a signal peptide (1–30 amino acids), a prodomain (amino acids 31–152), a catalytic domain (amino acids 153–421) and a C-terminal domain (amino acids 422–692). The molecular weight of proPCSK9 is 75 kDa, and the mature form is 62 kDa. Following autocatalytic cleavage in the endoplasmic reticulum, the prodomain is separated from the 62 kDa mature PCSK9 protein and both are secreted following the formation of a prosegment-PCSK9 complex. SP, signal peptide; PCSK9, proprotein convertase subtilisin/kexin type 9.
Fig. 1. PCSK9 protein structure PCSK9 comprises a signal peptide (1–30 amino acids), a prodomain (amino acids 31–152), a catalytic domain (amino acids 153–421) and a C-terminal domain (amino acids 422–692). The molecular weight of proPCSK9 is 75 kDa, and the mature form is 62 kDa. Following autocatalytic cleavage in the endoplasmic reticulum, the prodomain is separated from the 62 kDa mature PCSK9 protein and both are secreted following the formation of a prosegment-PCSK9 complex. SP, signal peptide; PCSK9, proprotein convertase subtilisin/kexin type 9.CC BY-NC-SA · PubMed Central
Fig. 2. SREBP-2-mediated co-expression of LDLR and PCSK9 Statin-induced reduction of the cholesterol pool in hepatocyte activates SREBP-2-medicated LDLR expression, thereby increasing hepatic LDL-C uptake. Concurrently, SREBP-2 up-regulates the expression of PCSK9 and enhances hepatic LDLR degradation. Thus, SREBP-2-mediated co-expression of LDLR and PCSK9 prevent excessive cholesterol uptake in hepatocytes in order to preserve cholesterol homeostasis. SREBP-2, sterol-regulatory element binding protein-2; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.
Fig. 2. SREBP-2-mediated co-expression of LDLR and PCSK9 Statin-induced reduction of the cholesterol pool in hepatocyte activates SREBP-2-medicated LDLR expression, thereby increasing hepatic LDL-C uptake. Concurrently, SREBP-2 up-regulates the expression of PCSK9 and enhances hepatic LDLR degradation. Thus, SREBP-2-mediated co-expression of LDLR and PCSK9 prevent excessive cholesterol uptake in hepatocytes in order to preserve cholesterol homeostasis. SREBP-2, sterol-regulatory element binding protein-2; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 133

Metadata

Authors
Nozue, T.
Affiliations
Yokohama Sakae Kyosai Hospital (JP)
Corresponding author
Nozue, Tsuyoshi
Venue
Journal of Atherosclerosis and Thrombosis
Published
2017
Volume
24
Issue
9
Pages
895-907
ISSN
  • 1340-3478 (ISSN-L)
  • 1880-3873
OpenAlex
W2743198652
Cited by
127
References
100
Citations by year
2026: 4 · 2025: 19 · 2024: 13 · 2023: 11 · 2022: 18 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 11
FWCI
2.61
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PCSK9, statins, LDL cholesterol lowering, hypercholesterolemia, LDL receptor degradation, cholesterol homeostasis, PCSK9 inhibitors, PCSK9 monoclonal antibodies, lipid metabolism biomarkers, cardiovascular risk
MeSH terms
Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Hypolipidemic Agents, Humans, Hypercholesterolemia, Cholesterol, LDL, Niacin, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Gene Silencing, Lipid Metabolism, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid Lowering Therapy and Circulating PCSK9 Concentration. https://app.cochat.ai/papers/10.5551/jat.rv17012
The paper
Nozue, T. (2017). Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.rv17012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.